Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Bolt Biotherapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +4 vs. Q4 2025
- Shares held
- 613.3K
- +20.9K (+3.5%) vs. Q4 2025
- Total value
- $2.49M
- −$751.1K (−23.2%) vs. Q4 2025
- New holders
- 6
- 6 more added
- Sold out
- 2
- 3 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 137,721 | $556.4K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 77,225 | $312.0K | 0.00% | +22,200+40.3% | Added |
| Vivo Capital, LLC | 72,414 | $292.6K | 0.02% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 42,581 | $172.0K | 0.06% | −51,992−55.0% | Reduced |
| T3 Companies, LLC | 38,000 | $153.5K | 0.21% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 35,977 | $145.3K | 0.02% | 00.0% | Unchanged |
| Pfizer Inc | 31,305 | $137.1K | 0.06% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 30,800 | $124.4K | 0.02% | +30,800 | New |
| Nan Fung Group Holdings Ltd | 29,250 | $118.2K | 0.10% | −29,097−49.9% | Reduced |
| Geode Capital Management, LLC | 28,791 | $116.3K | 0.00% | +9,988+53.1% | Added |
| Nano Cap New Millennium Growth Fund L P | 27,500 | $111.1K | 0.10% | +7,000+34.1% | Added |
| Shay Capital LLC | 14,905 | $60.2K | 0.01% | −367−2.4% | Reduced |
| Susquehanna International Group, LLP | 11,657 | $47.1K | 0.00% | +11,657 | New |
| Citadel Advisors LLC | 10,109 | $40.8K | 0.00% | +10,109 | New |
| BlackRock, Inc. | 9,711 | $39.2K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,060 | $28.5K | 0.00% | +7,060 | New |
| Morgan Stanley | 3,189 | $12.9K | 0.00% | +61+2.0% | Added |
| Vanguard Fiduciary Trust Co | 3,095 | $12.5K | 0.00% | +3,095 | New |
| Tower Research Capital LLC (TRC) | 1,093 | $4.42K | 0.00% | +370+51.2% | Added |
| UBS Group AG | 787 | $3.18K | 0.00% | +272+52.8% | Added |
| JPMorgan Chase & Co | 42 | $179 | 0.00% | 00.0% | Unchanged |
| Vanguard Global Advisers, LLC | 24 | $97 | 0.00% | +24 | New |
| SBI Securities Co., Ltd. | 10 | $40 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 6 | $24 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 0 | $0 | 0.00% | −256−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |